

CITATION REPORT

List of articles citing

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

DOI: 10.4155/bio.12.299

Bioanalysis, 2013, 5, 201-26.

Source: <https://exaly.com/paper-pdf/56791725/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
191	Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. <i>Bioanalysis</i> , 2013 , 5, 1057-71	2.1	93
190	Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. 2013 , 67, 382-91		32
189	Targeted delivery of anticancer agents using antibodies as vectors. 2013 , 6, 262-266		
188	Strategies to address drug interaction potential for antibody-drug conjugates in clinical development. <i>Bioanalysis</i> , 2013 , 5, 1115-30	2.1	18
187	Pharmacokinetic studies of protein drugs: past, present and future. 2013 , 65, 1065-73		45
186	Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. 2013 , 17, 406-11		43
185	Bioanalysis special focus issue on antibody-drug conjugates. <i>Bioanalysis</i> , 2013 , 5, 981-3	2.1	17
184	Antibody-drug conjugate drug development: where are the challenges?. <i>Bioanalysis</i> , 2013 , 5, 1467-9	2.1	
183	Discovery fit-for-purpose ligand-binding PK assays: what's really important?. <i>Bioanalysis</i> , 2013 , 5, 1463-6	2.1	4
182	Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery. <i>Bioanalysis</i> , 2013 , 5, 985-7	2.1	9
181	Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. <i>Bioanalysis</i> , 2013 , 5, 1041-55	2.1	27
180	2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS. <i>Bioanalysis</i> , 2013 , 5, 2903-18	2.1	55
179	Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. <i>Bioanalysis</i> , 2013 , 5, 997-1006	2.1	118
178	Bioanalysis annual round-up: the bioanalysis editorial team is delighted to welcome you to this mid-year round-up. <i>Bioanalysis</i> , 2013 , 5, 2227-31	2.1	
177	PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. <i>Bioanalysis</i> , 2013 , 5, 1025-40	2.1	47
176	Life cycle management of critical ligand-binding reagents. <i>Bioanalysis</i> , 2013 , 5, 2679-96	2.1	19
175	Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective. <i>Bioanalysis</i> , 2013 , 5, 989-92	2.1	18

174	Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. <i>Bioanalysis</i> , 2013 , 5, 1007-23	2.1	39
173	Bioanalysis of antibodydrug conjugates. 2013 , 6-16		
172	MS and antibody-based approaches for the analysis of biotherapeutics. 2013 , 18-31		
171	ISR: background, evolution and implementation, with specific consideration for ligand-binding assays. <i>Bioanalysis</i> , 2014 , 6, 393-402	2.1	7
170	The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis. <i>Bioanalysis</i> , 2014 , 6, 1827-41	2.1	19
169	2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). <i>Bioanalysis</i> , 2014 , 6, 3237-49	2.1	36
168	Interference in immunoassays to support therapeutic antibody development in preclinical and clinical studies. <i>Bioanalysis</i> , 2014 , 6, 1939-51	2.1	22
167	The 'blended' bioanalytical laboratory: the marriage of antibody- and instrument-based methods and expertise. <i>Bioanalysis</i> , 2014 , 6, 717-9	2.1	
166	Applications of low-flow LC-SRM for the analysis of large molecules in pharmaceutical R&D. <i>Bioanalysis</i> , 2014 , 6, 1859-67	2.1	9
165	Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. 2014 , 42, 1858-66		38
164	Antibody-drug conjugates: an emerging concept in cancer therapy. 2014 , 53, 3796-827		667
163	New challenges and opportunities in nonclinical safety testing of biologics. 2014 , 69, 226-33		20
162	A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. <i>AAPS Journal</i> , 2014 , 16, 488-98	3.7	46
161	Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. <i>Analytical Chemistry</i> , 2014 , 86, 3420-5	7.8	60
160	Antibody-drug conjugates: an emerging modality for the treatment of cancer. 2014 , 1321, 41-54		62
159	Assessment of the metabolism of therapeutic proteins and antibodies. 2014 , 10, 1079-91		15
158	Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 6949-64	8.3	311
157	Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates. 2014 , 28, 383-91		17

156	Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis. <i>Bioanalysis</i> , 2014 , 6, 79-87	2.1	28
155	Antikörper-Wirkstoff-Konjugate: ein neues Konzept in der Krebstherapie. 2014 , 126, 3872-3904		61
154	Liquid chromatography mass spectrometry quantitative bioanalysis of proteins. 2015 , 168-193		
153	Clinical pharmacology and assay consideration for characterizing pharmacokinetics and understanding efficacy and safety of antibody-drug conjugates. 2015 , 36-55		3
152	Application of ligand-binding assays for bioanalysis of antibody-drug conjugates. 2015 , 20-35		
151	Analytical assays for antibody-drug conjugate selection and development. 2015 , 56-68		
150	Pharmacokinetics and pharmacology of antibody-drug conjugates. 2015 , 120-135		
149	Bioanalytical Assay for Characterization of Antibody-Drug Conjugates (ADCs). <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 97-115	0.5	1
148	Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics. 2015 ,		2
147	Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate. <i>Molecular Pharmaceutics</i> , 2015 , 12, 1730-7	5.6	4
146	Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics. <i>AAPS Journal</i> , 2015 , 17, 1-16	3.7	127
145	Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. <i>Pharmaceutical Research</i> , 2015 , 32, 1907-19	4.5	15
144	Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015 , 32, 3470-9	4.5	71
143	Biotransformation and stability of antibody-drug conjugates: payload metabolism and linker cleavage delineation. <i>Bioanalysis</i> , 2015 , 7, 1319-23	2.1	7
142	Strategies for improving sensitivity and selectivity for the quantitation of biotherapeutics in biological matrix using LC-MS/MS. 2015 , 12, 125-31		11
141	An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015 , 32, 3584-92	4.5	4
140	Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 ,	0.5	6
139	Emerging formats for next-generation antibody drug conjugates. 2015 , 10, 463-81		48

138	Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015 , 42, 553-71	2.7	26
137	Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC-MS/MS approach: Assay development, validation, and a case study. 2015 , 1002, 54-62		44
136	Message from the editors. <i>Bioanalysis</i> , 2015 , 7, 1-4	2.1	
135	In vivo biotransformations of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1649-64	2.1	34
134	Bioanalysis of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1559-60	2.1	7
133	An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. <i>Bioanalysis</i> , 2015 , 7, 1569-82	2.1	25
132	Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. <i>Bioanalysis</i> , 2015 , 7, 1605-17	2.1	20
131	Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1583-604	2.1	26
130	Challenges in antibody-drug conjugate discovery: a bioconjugation and analytical perspective. <i>Bioanalysis</i> , 2015 , 7, 1561-4	2.1	10
129	Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. 2015 , 54, 81-93		33
128	Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. <i>AAPS Journal</i> , 2015 , 17, 35-43	3.7	49
127	An Overall Comparison of Small Molecules and Large Biologics in ADME Testing. 2016 , 4, 1		20
126	. 2016 ,		4
125	Boston Society's 11th Annual Applied Pharmaceutical Analysis conference. <i>Bioanalysis</i> , 2016 , 8, 259-64	2.1	1
124	(Bio) analysis of biosimilars. 2016 , 124-137		
123	Immunogenicity and its effect on pharmacokinetics of biotherapeutics. 2016 , 68-82		
122	Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 665-673	4.5	8
121	Current Issues in Ligand Binding Assay Bioanalysis. 2016 ,		

120 Ligand binding assays: calibration curves. **2016**, 34-46

119 Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. **2016**, 21, 850-5 33

118 New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. **2016**, 44, 897-910 9

117 The flexibility of a generic LC-MS/MS method for the quantitative analysis of therapeutic proteins based on human immunoglobulin G and related constructs in animal studies. **2016**, 131, 214-222 10

116 Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate. *Bioanalysis*, **2016**, 8, 2205-2217 2.1 18

115 Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB antibody antibiotic conjugate against *Staphylococcus aureus* in mice. *MABs*, **2016**, 8, 1612-1619 6.6 39

114 Challenges and advances in the assessment of the disposition of antibody-drug conjugates. **2016**, 37, 66-74 33

113 Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS. *Bioanalysis*, **2016**, 8, 1663-78 2.1 25

112 Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques. **2016**, 1032, 39-50 46

111 Techniques for quantitative LC-MS/MS analysis of protein therapeutics: advances in enzyme digestion and immunocapture. *Bioanalysis*, **2016**, 8, 847-56 2.1 27

110 Pharmacokinetics of Antibody Drug Conjugates. **2016**, 245-266

109 QC Assay Development. **2016**, 131-149

108 Bioanalytical Strategies Enabling Successful ADC Translation. **2016**, 177-205

107 Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. **2016**, 82, 1-13 26

106 Custom-Designed Affinity Capture LC-MS F(ab')₂ Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. *Analytical Chemistry*, **2016**, 88, 11340-11346 7.8 47

105 A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species. **2016**, 1032, 149-154 13

104 Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. *Bioanalysis*, **2016**, 8, 1383-401 2.1 24

103 Investigation of low recovery in the free drug assay for antibody drug conjugates by size exclusion-reversed phase two dimensional-liquid chromatography. **2016**, 1032, 112-118 11

102	Adaptation of hybrid immunoaffinity LC-MS methods for protein bioanalysis in a Contract Research Organization. <i>Bioanalysis</i> , 2016 , 8, 1545-1549	2.1	3
101	Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. 2016 , 44, 617-23		59
100	Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates. <i>Bioanalysis</i> , 2016 , 8, 55-63	2.1	29
99	Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. <i>Analytical Chemistry</i> , 2016 , 88, 695-702	7.8	41
98	Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals. <i>Analytical Chemistry</i> , 2016 , 88, 480-507	7.8	162
97	Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. <i>MAbs</i> , 2016 , 8, 229-45	6.6	77
96	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 439-47	6.1	68
95	Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins. <i>AAPS Journal</i> , 2016 , 18, 424-31	3.7	6
94	Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matrices. <i>Bioanalysis</i> , 2016 , 8, 519-31	2.1	2
93	Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. 2016 , 120, 322-32		17
92	Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections. 2017 , 23, 135-149		64
91	High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization of in Vivo Biotransformations for Intact Antibody-Drug Conjugates. <i>Analytical Chemistry</i> , 2017 , 89, 5476-5483	7.8	35
90	Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development. 2017 , 183-201		1
89	The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics. 2017 , 67-89		
88	Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. <i>British Journal of Pharmacology</i> , 2017 , 174, 628-640	8.6	20
87	Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 537-548	2.7	8
86	Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. <i>Journal of Clinical Pharmacology</i> , 2017 , 57 Suppl 10, S11-S25	2.9	27
85	Characterization of AntibodyDrug Conjugates. 2017 , 155-168		

84	Immunoprecipitation middle-up LC-MS for in vivo drug-to-antibody ratio determination for antibody-drug conjugates. <i>Bioanalysis</i> , 2017 , 9, 1535-1549	2.1	12
83	Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. <i>AAPS Journal</i> , 2017 , 19, 130-140	3.7	10
82	Accelerating Regulated Bioanalysis for Biotherapeutics: Case Examples Using a Microfluidic Ligand Binding Assay Platform. <i>AAPS Journal</i> , 2017 , 19, 82-91	3.7	3
81	Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis. <i>Bioanalysis</i> , 2017 , 9, 1883-1893	2.1	19
80	Emerging Bioanalytical Methods for the Bioanalysis of Biotherapeutics. 2017 , 180-197		
79	A single liquid chromatography-quadrupole time-of-flight mass spectrometric method for the quantification of total antibody, antibody-conjugated drug and free payload of antibody-drug conjugates. <i>Biomedical Chromatography</i> , 2018 , 32, e4229	1.7	3
78	Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification. <i>Bioconjugate Chemistry</i> , 2018 , 29, 1155-1167	6.3	37
77	An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 638-649	6.1	19
76	LCMS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. <i>Current Pharmacology Reports</i> , 2018 , 4, 45-63	5.5	13
75	LC/MS/MS Bioanalysis of Protein-Drug Conjugates-The Importance of Incorporating Succinimide Hydrolysis Products. <i>Analytical Chemistry</i> , 2018 , 90, 5314-5321	7.8	9
74	Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 989-1000	8.3	41
73	Perspectives on potentiating immunocapture-LC-MS for the bioanalysis of biotherapeutics and biomarkers. <i>Bioanalysis</i> , 2018 , 10, 1679-1690	2.1	8
72	Bioanalytical workflow for novel scaffold protein-drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin-drug conjugate in plasma and tissue samples using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> , 2018 , 10, 1651-1665	2.1	10
71	Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody-Drug Conjugate Modifications. <i>Antibodies</i> , 2018 , 7,	7	1
70	ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. <i>Antibodies</i> , 2018 , 7,	7	18
69	Optimizing hybrid LC-MS/MS binding conditions is critical: impact of biotransformation on quantification of trastuzumab. <i>Bioanalysis</i> , 2018 ,	2.1	12
68	Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection. <i>AAPS Open</i> , 2018 , 4,	2.2	2
67	Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS. <i>Bioanalysis</i> , 2018 ,	2.1	14

66	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. <i>MAbs</i> , 2018 , 10, 1312-1321	6.6	10
65	Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. <i>MAbs</i> , 2018 , 10, 960-967	6.6	12
64	In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 120, 89-95	5.1	1
63	Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 606-615	4.5	3
62	Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. <i>Bioanalysis</i> , 2019 , 11, 1555-1568	2.1	14
61	Preclinical and translational pharmacokinetics of a novel THIOMAB [®] antibody-antibiotic conjugate against. <i>MAbs</i> , 2019 , 11, 1162-1174	6.6	13
60	Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data. <i>Clinical and Translational Science</i> , 2019 , 12, 534-544	4.9	10
59	Protein quantification by LC-MS: a decade of progress through the pages of. <i>Bioanalysis</i> , 2019 , 11, 629-644		33
58	A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	33
57	Sample Preparation for LC-MS Bioanalysis of AntibodyDrug Conjugates. 2019 , 335-350		1
56	Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte. <i>Analytical and Bioanalytical Chemistry</i> , 2019 , 411, 2587-2596	4.4	3
55	Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2. <i>Antibodies</i> , 2019 , 8,	7	23
54	Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. <i>Bioconjugate Chemistry</i> , 2019 , 30, 1356-1370	6.3	9
53	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 17	7	21
52	Immunoaffinity LC-MS/MS to quantify a PEGylated anti-Factor D Fab biotherapeutic in cynomolgus monkey serum. <i>Bioanalysis</i> , 2019 , 11, 2161-2173	2.1	4
51	. 2019 ,		6
50	An LC/MS based method to quantify DNA adduct in tumor and organ tissues. <i>Analytical Biochemistry</i> , 2019 , 568, 1-6	3.1	3
49	Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2020 ,	1.4	0

48	Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies. <i>Analytical Chemistry</i> , 2020 , 92, 2065-2073	7.8	15
47	Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. <i>MABs</i> , 2020 , 12, 1699768	6.6	12
46	Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020 , 9, 48-59	4.5	14
45	Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates. <i>Journal of Clinical Pharmacology</i> , 2020 , 60 Suppl 1, S105-S119	2.9	3
44	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. <i>Pharmaceutical Research</i> , 2020 , 37, 252	4.5	0
43	Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2020 , 92, 12168-12175	7.8	6
42	Characterizing and Quantitating Therapeutic Tethered Multimeric Antibody Degradation Using Affinity Capture Mass Spectrometry. <i>Analytical Chemistry</i> , 2020 , 92, 6839-6843	7.8	4
41	Antibody Subunit LC-MS Analysis for Pharmacokinetic and Biotransformation Determination from In-Life Studies for Complex Biotherapeutics. <i>Analytical Chemistry</i> , 2020 , 92, 8268-8277	7.8	8
40	Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 158, 631-639	4.9	8
39	IQ consortium perspective: complementary LBA and LC-MS in protein therapeutics bioanalysis and biotransformation assessment. <i>Bioanalysis</i> , 2020 , 12, 257-270	2.1	11
38	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 364-372	12.9	12
37	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 831-842	3.5	7
36	Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. <i>Molecules</i> , 2020 , 25,	4.8	10
35	Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates. <i>Molecular Pharmaceutics</i> , 2021 , 18, 889-897	5.6	4
34	Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
33	What makes a good antibody-drug conjugate?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 841-847	5.4	7
32	Automated and Faster Affinity Capture Method for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2021 , 93, 5371-5376	7.8	4
31	Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. <i>Analytical Chemistry</i> , 2021 , 93, 6135-6144	7.8	7

30	Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 743-765	3.5	3
29	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2021 , 112, 2845-2854	6.9	5
28	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4511-4520	12.9	10
27	The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics. <i>Bioanalysis</i> , 2021 , 13, 931-954	2.1	2
26	Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody-drug conjugates. <i>Bioanalysis</i> , 2021 ,	2.1	1
25	LC/MS versus Immune-Based Bioanalytical Methods in Quantitation of Therapeutic Biologics in Biological Matrices. 1-17		1
24	High-Resolution Characterization of ADCs by Orbitrap LCMS. <i>Methods in Molecular Biology</i> , 2020 , 2078, 213-219	1.4	2
23	Determination of ADC Concentration by Ligand-Binding Assays. <i>Methods in Molecular Biology</i> , 2020 , 2078, 361-369	1.4	3
22	Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 117-131	0.5	1
21	Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. <i>Journal of Pharmaceutical Analysis</i> , 2020 , 10, 209-220	14	18
20	Ligand binding assay measurement of antibodydrug conjugates. 2016 , 110-123		1
19	Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	3
18	Investigating the Nonclinical ADME and PK/PD of an AntibodyDrug Conjugate: A Case Study of Ado-Trastuzumab Emtansine (T-DM1). 1-11		
17	Novel methods to characterize antibodydrug conjugates (DAR and PK emphasis). 2015 , 70-88		
16	Introduction to Antibody-Drug Conjugates. <i>Antibodies</i> , 2021 , 10,	7	5
15	ADME of Biologicals and New Therapeutic Modalities. 2021 ,		
14	Enzyme-linked immunosorbent assays for quantification of MMAE-Conjugated ADCs and total antibodies in cynomolgus monkey sera. <i>Journal of Pharmaceutical Analysis</i> , 2021 ,	14	0
13	Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.. <i>Pharmaceutical Research</i> , 2022 , 39, 1	4.5	4

12	Multiplexed Quantitative Analysis of Antibody-Drug Conjugates with Labile CBI-Dimer Payloads Using Immunoaffinity LC-MS/MS.. <i>Analytical Chemistry</i> , 2021 ,	7.8	0
11	Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. <i>Pharmaceuticals</i> , 2022 , 15, 508	5.2	1
10	An Introduction to Bioanalysis of Bispecific and Fusion Proteins. 2022 , 75-102		0
9	An Introduction to Bioanalysis of Antibody-Drug Conjugates. 2022 , 49-74		0
8	Current Analytical Strategies for AntibodyDrug Conjugates in Biomatrices. 2022 , 27, 6299		1
7	Detection of antibody-conjugate payload in cynomolgus monkey serum by a high throughput capture LC-MS/MS bioanalysis method. 2022 , 115069		0
6	ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs). 1-44		0
5	AntibodyDrug Conjugates: Development and Applications. 2022 , 127-154		0
4	Implementation of Systematic Bioanalysis of AntibodyDrug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats. 2023 , 15, 756		0
3	Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 14,		0
2	Pharmacokinetic Study of Antibody-Drug Conjugates. 2023 , 117-135		0
1	Determination of Drug-to-Antibody Ratio of ADCs. 2023 , 101-115		0